Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza

New England Journal of Medicine

Volumn 341, Issue 18, 1999, Pages 1336-1343

  Hayden, Frederick G ^a,i   Atmar, Robert L ^b   Schilling, Margo ^c   Johnson, Casey ^d   Poretz, Donald ^e   Paar, David ^f   Huson, Les ^g   Ward, Penelope ^g   Mills, Roger G ^h  

^a UNIVERSITY OF VIRGINIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d Pharmaceutical Research Associates Inc   (United States)

^e Infectious Diseases Physicians   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g ROCHE PRODUCTS LTD   (United Kingdom)

^h GILEAD SCIENCES   (United States)

ⁱ UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURAL FACTOR; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NEURAMINIDASE; OSELTAMIVIR;

EID: 0032696188     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199910283411802     Document Type: Article

References (28)

1. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47(RR-6):1-26.
2. Update: influenza activity - United States, 1997-98 season. MMWR Morb Mortal Wkly Rep 1998;47:196-200.
3. Van Voris LP, Belshe RB, Shaffer JL. Nosocomial influenza B virus infection in the elderly. Ann Intern Med 1982;96:153-8.
4. Libow LS, Neufeld RR, Olson E, Breuer B, Starer P. Sequential outbreak of influenza A and B in a nursing home: efficacy of vaccine and amantadine. J Am Geriatr Soc 1996;44:1153-7.
5. Subbarao K, Klimov I, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998;279:393-6.
6. Claas EC, Osterhaus AD, van Beck R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998;351: 472-7 [Erratum, Lancet 1998;351:1292.]
7. Yuen KY, Chan PK, Peiris M, et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 1998;351:467-71.
8. Hayden FG. Antivirals for pandemic influenza. J Infect Dis 1997;176: Suppl 1:S56-S61.
9. Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. J Infect Dis 1997;176:Suppl 1:S32-S37.
10. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580-4.
11. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995;39:2224-8.
12. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of adverse effects (AEs) of amantadine (AM) and rimantadine (RM) used as sequential prophylaxis of influenza A (FLU) in elderly nursing home residents. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 24-27, 1998. Washington, D.C.: American Society for Microbiology, 1998:335. abstract.
13. Hayden FG. Amantadine and rimantadine - clinical aspects. In: Richman DD, ed. Antiviral drug resistance. Chichester, England: John Wiley, 1996:59-77.
14. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 1998;56:537-53.
15. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997;119:681-90.
16. Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 1998;42:640-6.
17. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42:647-53.
18. Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res 1998;37:107-20.
19. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized, controlled trials. JAMA (in press).
20. Wood ND, Aitken M, Sharp S, Evison H. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro-64-0802 (GS4071) following oral administration of the prodrug Ro-64-0796 (GS4104) to healthy male volunteers. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997. Washington, D.C.: American Society for Microbiology, 1997:25. abstract.
21. Aoki FY, Osterhaus AD, Rimmelzwaan GF, Kinnersley N, Ward P. Oral oseltamivir successfully reduces duration and severity of naturally acquired influenza. In: Final program, abstracts, and exhibits addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 24-27, 1998. Washington, D.C.: American Society for Microbiology, 1998:22. abstract.
22. Treanor JJ, Vrooman PS, Hayden FG, et al. Efficacy of oral GS4104 in treating acute influenza. In: Final program, abstracts, and exhibits addendum of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., September 24-27, 1998. Washington, D.C.: American Society for Microbiology, 1998:21. abstract.
23. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem 1979;94:287-96.
24. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for P-value adjustment. New York: John Wiley, 1993.
25. Noethcr G. Two confidence intervals for the ratio of two probabilities and some measures of effectiveness. J Am Stat Assoc 1957;52:36-45.
26. Calfee DP, Peng EW, Hufsey EK, Lobo M, Hayden FG. Protective efficacy of reduced frequency dosing of intranasal zanamivir in experimental human influenza. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-Octobcr 1, 1997. Washington, D.C.: American Society for Microbiology, 1998:334. abstract.
27. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-5.
28. Douglas RG Jr. Prophylaxis and treatment of influenza. N Engl J Med 1990;322:443-50.